The European Commission has approved Boehringer Ingelheim’s and Eli Lilly and Company’s Synjardy, a new single-pill combination therapy to treat Type II diabetes. The drug is part of the companies’ diabetes alliance.

Synjardy combines empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), commonly prescribed for the treatment of Type II diabetes. Empagliflozin was approved in the European Union in May 2014 and is available in many countries as an oral, once-daily tablet, marketed as Jardiance.

Synjardy is indicated for use alongside diet and exercise to improve blood glucose control in adults with Type II diabets when they are: (1) inadequately controlled on their maximally tolerated dose of metformin alone; inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin; or already being treated with the combination of empagliflozin and metformin as separate tablets.

Source: Boehringer Ingelheim